Next Article in Journal
Bilateral Simultaneous Breast Reconstruction with DIEP- and TMG Flaps: Head to Head Comparison, Risk and Complication Analysis
Next Article in Special Issue
Does SARS-CoV-2 Trigger Stress-Induced Autoimmunity by Molecular Mimicry? A Hypothesis
Previous Article in Journal
Mathematical Model of Muscle Wasting in Cancer Cachexia
Previous Article in Special Issue
Clinical-Forensic Autopsy Findings to Defeat COVID-19 Disease: A Literature Review
Open AccessReview

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19

1
IIS-Fundación Jiménez Diaz, Department of Medicine, School of Medicine, Universidad Autónoma de Madrid, 28029 Madrid, Spain
2
Red de Investigación Renal (REDINREN), Instituto Carlos III-FEDER, 28040 Madrid, Spain
3
Department of Nephrology, Hospital Clínico Universitario, INCLIVA, 46010 Valencia, Spain
4
Medicine Department, Universidad de Valencia, 46010 Valencia, Spain
5
Nephrology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Nephrology Research Group, Vall d’Hebron Research Institute, 08035 Barcelona, Spain
6
Department of Medicine, Division of Nephrology, Koc University School of Medicine, 43010 Istanbul, Turkey
7
Department of Medicine, Hospital Universitario de Canarias, 38320 Tenerife, Spain
8
Instituto de Tecnologías Biomédicas, University of La Laguna, 38320 Tenerife, Spain
9
Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(7), 2030; https://doi.org/10.3390/jcm9072030
Received: 28 May 2020 / Revised: 16 June 2020 / Accepted: 22 June 2020 / Published: 28 June 2020
(This article belongs to the Special Issue COVID-19: From Pathophysiology to Clinical Practice)
Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboembolic complications and replacing or supporting organ function. However, despite organ support, mortality is currently 65% for those receiving advanced respiratory support and 78% for those requiring renal replacement therapies. Thus, efforts should be made to provide adjuvant organ protection therapy. This may imply novel therapies in clinical development (e.g., the Fas ligand trap asunercept), but uptake of repurposed drugs already in clinical use may be faster. In this regard, sodium glucose co-transporter-2 (SGLT2) inhibitors were recently shown to protect the heart and kidney both within and outside of a diabetic milieu context. Further, preclinical data support a beneficial effect for the lung. We now discuss the potential benefits and risks of SGLT2 inhibitors in COVID-19 and an ongoing clinical trial testing the impact of dapagliflozin on outcomes in COVID-19 patients with respiratory failure. View Full-Text
Keywords: COVID-19; diabetes; chronic kidney disease; cardiovascular; SGLT2; canagliflozin; dapagliflozin; empagliflozin COVID-19; diabetes; chronic kidney disease; cardiovascular; SGLT2; canagliflozin; dapagliflozin; empagliflozin
Show Figures

Figure 1

MDPI and ACS Style

Fernandez-Fernandez, B.; D’Marco, L.; Górriz, J.L.; Jacobs-Cachá, C.; Kanbay, M.; Luis-Lima, S.; Porrini, E.; Sarafidis, P.; Soler, M.J.; Ortiz, A. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. J. Clin. Med. 2020, 9, 2030.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop